Orforglipron Dosing Explained: Monthly Titration and Color Coded Tablets for Obesity Care

The US FDA recently approved orforglipron (Foundayo™, Eli Lilly) for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction in adults with obesity or overweight in the presence of at least 1 weight-related comorbid condition.¹

The agency's decision was based on data from the ATTAIN phase 3 global clinical development program, which showed superior glycemic control among 4500 participants across 2 registration trials.²

As clinicians prepare for the rollout of orforglipron, one of the most practical questions will be how to manage dose titration and day-to-day prescribing in busy primary care and endocrine settings. In their discussion on Diabetes Dialog: Technology, Therapeutics and Real-World Perspectives, Diana Isaacs, PharmD, and Natalie Bellini, DNP, highlighted key details about the drug’s stepwise dosing strategy—and why its color‑coded tablets could meaningfully reduce confusion at the point of care.

Monthly Titration With Non-Linear Dose Steps

Similar to other GLP-1–based therapies, orforglipron is designed to be titrated monthly:

• Start at 0.8 mg for at least 4 weeks
• Then escalate through: 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg

Unlike agents such as tirzepatide, which typically increase in consistent 2.5‑mg increments, orforglipron’s dose steps are non-linear. Bellini noted this as a key difference clinicians will have to internalize when building protocols or order sets.

Both clinicians emphasized the usual GLP-1 principle still applies:

Start low, go slow, and titrate according to tolerability and response.

However, Isaacs pointed out an emerging gray area: transitioning patients from higher-dose injectable GLP-1s to oral orforglipron. In practice, clinicians may be reluctant to “go all the way back to zero” when switching, but may still need to balance prior progress with the risk of GI adverse effects. Bellini described this as an area where “medicine is art,” underscoring that clinical judgment and patient-specific factors will drive real-world titration choices.

Color-Coded Tablets to Reduce Medication Confusion

One of the most practical, and potentially underappreciated, design elements of orforglipron is that each dose strength is color coded.

Bellini compared this to levothyroxine, where 88 mcg, 100 mcg, and other strengths reliably correspond to specific tablet colors across brands and generics. Orforglipron adopts a similar strategy:

• Each dose strength has its own distinct color
• Pill shape and color become quick identifiers during telehealth or phone encounters

This design allows clinicians to verify regimens with simple questions such as:

• “Are you taking the pink pill or the yellow pill?”
• “Is your tablet oval or a different shape?”

For patients with complex medication lists, language barriers, limited health literacy, or incomplete records, this could streamline medication reconciliation and reduce dosing errors—especially during titration or when records are not immediately accessible.

Transitioning From Trials to Real-World Use

While detailed transition algorithms from injectables to orforglipron have yet to be standardized, Isaacs and Bellini’s discussion underscores several early clinical takeaways:

• Expect to individualize starting doses when converting from high-dose injectables.
• Use the color‑coded tablets as a practical safety net to confirm what patients are actually taking.
• Anticipate that some aspects of orforglipron use—particularly switching and up‑titration—will initially be guided by clinical “art”, then refined as real‑world data accumulate.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

References:

1. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. News release. April 1, 2026. Accessed April 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
2. Eli Lilly. Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes. News release. October 15, 2025. Accessed April 16, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-superior-glycemic